These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 27905158)
1. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma. McGrane J; Carswell S; Talbot T Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158 [TBL] [Abstract][Full Text] [Related]
2. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Meani RE; Lim SW; Chang AL; Kelly JW Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162 [TBL] [Abstract][Full Text] [Related]
3. Current landscape for treatment of advanced basal cell carcinoma. Foley P Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811 [TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490 [TBL] [Abstract][Full Text] [Related]
5. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas. Sobanko JF; Okman J; Miller C J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062 [TBL] [Abstract][Full Text] [Related]
6. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876 [TBL] [Abstract][Full Text] [Related]
7. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications. Bayers S; Kapp DL; Beer KR; Slavin B J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060 [TBL] [Abstract][Full Text] [Related]
8. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279 [TBL] [Abstract][Full Text] [Related]
9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma. Lyseng-Williamson KA; Keating GM Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081 [TBL] [Abstract][Full Text] [Related]
10. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
11. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Cirrone F; Harris CS Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338 [TBL] [Abstract][Full Text] [Related]
12. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report. Awad R; Andrade JCB; Mousa H; Mahmoud F Perm J; 2018; 22():17-181. PubMed ID: 30005721 [TBL] [Abstract][Full Text] [Related]
14. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888 [TBL] [Abstract][Full Text] [Related]
15. Identifying patients at risk for recurrent or advanced BCC. Hamid O; Goldenberg G J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332 [TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727 [TBL] [Abstract][Full Text] [Related]
19. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]